How Closed-Loop Insulin Systems Work—and Why the Next Generation Is Getting Harder to Build

A hybrid closed-loop insulin system continuously reads your blood sugar through a glucose sensor, then automatically adjusts insulin delivery through a pump. It's called "hybrid" because you still need to tell it when you eat. The system handles the math and timing of insulin on its own—you don't.

Research shows these systems work. In studies comparing different hybrid closed-loop pumps, all of them increased the percentage of time people spent in their target glucose range compared to standard insulin therapy. On average, people using automated insulin delivery systems spent about 11.7% more time in range. That might not sound like much, but across a day or week, it translates to fewer extreme highs and lows.

A 2024 analysis comparing seven different hybrid closed-loop systems found a clear ranking in effectiveness. The Minimed 780G achieved the highest time in range, followed by Control-IQ, then Minimed 670G and others. But the differences between top performers were relatively modest—roughly 5 to 10 percentage points.

More importantly, all systems reduced dangerous low blood sugar episodes. The Minimed 780G, Minimed 670G, and DBLG-1 showed the largest reductions in time spent dangerously low. Severe hypoglycemia and diabetic ketoacidosis rates stayed similar to standard insulin therapy, meaning these systems didn't trade better average control for new safety risks.

Pregnancy with Type 1 diabetes carries serious risks—roughly half of pregnant women with Type 1 experience complications related to high blood sugar. Recent trials tested whether closed-loop systems could help. In a 2023 study of pregnant women in the United Kingdom, those using hybrid closed-loop therapy spent an average of 68% of time in pregnancy-specific target range, compared to 56% in the standard-care group. A similar Canadian and Australian trial found even larger differences: 65% in range with closed-loop versus 50% with standard care.

These improvements matter during pregnancy because even modest reductions in time spent high can lower the risk of serious complications. The systems were safe, with no unexpected safety signals in either trial.

Your body makes two hormones to control blood sugar: insulin brings it down, and glucagon brings it up. Current pumps only deliver insulin, so they can't prevent low blood sugar on their own. Engineers have been trying to build pumps that deliver both insulin and glucagon for over 20 years, and research shows dual-hormone systems do improve glucose control more than insulin-only systems.

The hold-up isn't the pump engineering—it's glucagon itself. Glucagon is a protein that degrades in liquid. Put it in water and within hours it starts to clump, forming fibers that thicken into a gel that clogs pump tubing. That's why emergency glucagon rescue kits are still powders you mix right before using. Researchers are working on solutions to keep glucagon stable in solution, but until that's solved, dual-hormone pumps will remain out of reach.

The next frontier is systems that require even less input from you. Researchers are developing fully automated artificial pancreas systems that don't need you to announce meals or exercise. One system in development, called FLEX-AP, uses flexible algorithms designed to handle unannounced meals and activity while still giving you the option to tell the pump when you want to.

Other research is exploring how individual factors—like dietary fat, menstrual cycle phases, and sex differences—affect insulin needs moment to moment. As these insights mature, future systems may be able to personalize insulin delivery even more precisely, bringing us closer to the automated blood sugar control a real pancreas provides.

Origin: YouTube / Shell | T1D + UGC Creator (Video report). Evidence: Video report, corroborated with 6 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.